Relmada Therapeutics RLMD Cash Flow Statement (2012-2026)

NASDAQ RLMD
$3.35 -0.01 (-0.30%)
As of: Oct 21, 2026 · 11:41 AM EDT
Reported Financials

Relmada Therapeutics Quarterly Cash Flow Statement

Periods 57 quarters
Latest Jun 2026

Relmada Therapeutics reported cash from operations of -$9.61M and free cash flow of -$9.61M for the quarter ended Jun 2026, down 50.1% year over year. This cash flow statement covers 57 quarters of results from May 2012 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow May2012 Aug2012 Nov2012 Feb2013 May2013 Aug2013 Nov2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-42.61M-34.38M-39.75M-39.93M-39.42M-37.94M-26.32M-25.30M-22.00M-25.17M-21.83M-17.77M-21.73M-18.66M-17.56M-9.87M-10.09M-19.87M-19.05M-12.91M
Depreciation and DepletionDep. & Depletion
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges
Depreciation & Amortization (CF)Dep. & Amort.
-1.30M
Share-based CompensationStock Comp.
18.26M8.12M11.93M12.30M8.34M11.63M11.35M11.17M11.39M9.89M8.30M7.21M7.95M6.73M3.57M3.45M3.61M2.37M0.96M0.90M
Gains from Equity InvestmentsGains Equity
-0.34M-0.12M-0.02M0.02M-0.56M-0.03M-0.67M
Gains from Investment SecuritiesGains Investment
-0.95M-0.32M1.29M-0.64M-0.58M-3.35M0.05M0.13M0.15M0.04M0.16M0.05M-0.08M0.37M-0.17M
Other non-cash itemsOther Non-Cash
5.08M
Change in Working Capital
Change in ReceivablesChange Receivables
-0.02M-0.02M-0.02M-0.02M-0.04M-0.51M
Change in InventoryChange Inventory
Change in Account PayablesChange Payables
2.25M-1.52M-0.52M3.22M-3.47M1.19M-0.84M0.43M-2.00M0.65M1.68M-1.01M-1.83M1.79M-2.87M0.10M0.09M0.12M1.76M-0.92M
Change in Accured ExpensesChange Accured Exp.
2.08M-1.67M0.87M6.64M-1.03M-3.14M-1.53M0.17M-0.28M3.12M-1.52M-1.81M0.38M0.42M-2.19M-0.19M-0.04M1.13M-1.56M1.71M
Change in Other Operating AssetsOther Assets Change
1.17M8.59M-6.24M-1.32M-0.81M1.61M-1.46M0.90M-1.14M-1.65M-0.43M-0.20M1.30M-0.98M-0.29M-0.12M0.71M-0.20M0.40M-0.07M
Change in Other Operating LiabilitiesOther Liabilities Change
0.00M
Other Working Capital ChangesOther WC Changes
-1.17M-8.59M6.24M1.32M0.81M-1.61M1.46M-0.90M1.14M1.65M0.43M0.20M-1.30M0.98M0.29M0.12M-0.71M0.20M-0.40M0.07M
Cash from OperationsCash from Ops.
-20.92M-37.66M-19.43M-21.63M-26.86M-35.88M-16.51M-13.27M-11.63M-10.25M-13.04M-13.26M-16.66M-8.80M-18.07M-6.40M-6.72M-14.60M-15.07M-9.61M
Investing Activities
Capital ExpendituresCapex
Change in Property, Plant and EquipmentChange in PP&E
Purchase of InvestmentsInvestments Purchased
25.60M140.51M25.92M7.50M5.58M8.30M34.77M10.81M11.57M33.31M7.01M1.30M3.11M0.65M0.49M0.32M0.23M82.79M149.52M24.75M
Sale and Maturity of InvestmentsInvestments Sold
53.12M49.32M15.89M7.36M37.14M6.65M74.77M9.66M15.43M41.05M17.07M15.31M19.26M12.00M15.85M7.00M6.99M5.86M14.29M42.34M
Change in Acquisitions & DivestmentsChange Acquisitions
Cash from Investing ActivitiesCash from Investing
27.51M-91.18M-10.03M-0.14M31.56M-1.66M40.00M-1.15M3.86M7.74M10.06M14.01M16.14M11.35M15.36M6.68M6.75M-76.93M-135.23M17.59M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance
Long-Term Debt RepaymentsLT Debt Repayment
Non-Current Debt
Current Debt
Net Debt Issuances and RepaymentsNet Debt Issuance
Change in Capital Stock
Common Stock IssuedStock Issued
-0.04M161.23M29.95M14.09M0.62M0.04M0.25M160.00M0.10M
Shares Repurchased
3.36M6.46M
Net Shares Issued and RepurchasedNet Shares Issued
-0.04M161.23M29.95M14.09M0.62M0.04M0.25M156.64M-6.35M
Net Equity Issued and RepurchasedNet Equity Issued
-0.04M161.23M29.95M14.09M0.62M0.04M0.25M156.64M-6.35M
Other financing activitiesOther financing
-0.03M-0.09M-0.17M-0.07M-0.07M
Cash from Financing ActivitiesCash from Financing
0.19M161.84M29.95M14.09M0.57M0.41M0.22M-0.09M-0.17M93.64M156.57M-6.42M
Additional items
Change in Cash
6.78M32.99M0.49M-7.67M5.26M-37.13M23.50M-14.43M-7.77M-2.61M-2.76M0.75M-0.60M2.37M-2.71M0.20M0.03M2.11M6.28M1.56M
Ending Cash Balance
11.45M44.44M44.93M37.26M42.52M5.40M28.89M14.47M6.70M4.09M1.34M2.09M1.48M3.86M1.15M1.35M1.38M3.50M9.78M11.33M
Free Cash FlowFCF
-20.92M-37.66M-19.43M-21.63M-26.86M-35.88M-16.51M-13.27M-11.63M-10.25M-13.04M-13.26M-16.66M-8.80M-18.07M-6.40M-6.72M-14.60M-15.07M-9.61M
Net Cash FlowNCF
6.78M32.99M0.49M-7.67M5.26M-37.13M23.50M-14.43M-7.77M-2.51M-2.76M0.75M-0.60M2.37M-2.71M0.28M0.03M2.11M6.28M1.56M
Interest Paid

Relmada Therapeutics Cash Flow Statement API

Pull Relmada Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=RLMD&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY